Streetbeat News

Regulatory

GOOG

GOOGL

Alphabet Inc (NASDAQ:GOOG)(NASDAQ:GOOGL) is set to report its Q3 earnings, with analysts expecting revenue of $86.34 billion and EPS of $1.85. The company has consistently beaten estimates in recent quarters. A potential breakup due to antitrust probes could increase shareholder value, with analysts suggesting Alphabet's parts are worth more separately. Key areas to watch include Google's search and YouTube segments, AI investments, and potential regulatory impacts.

Portfolio Pulse from Chris Katje

October 28, 2024 | 5:26 pm

NXST

Nexstar Media Group is set to acquire WBNX-TV/TV55 in Cleveland, creating a duopoly in the 19th largest US TV market. The station will become a CW affiliate in 2025. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 5:25 pm

BABA

JD

NIO

PDD

US-listed Chinese stocks are experiencing a rise in share prices following the People's Bank of China's announcement to use reverse repurchase agreements to enhance liquidity management, potentially boosting investor confidence.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 5:21 pm

EIS

ISRA

SPY

USO

The article discusses Israeli Prime Minister Netanyahu's decision to wait for the outcome of the U.S. presidential election before committing to a diplomatic path. This decision could impact geopolitical relations and market sentiment.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:46 pm

ATLX

Atlas Lithium shares rose after receiving an operational permit for its Neves Project in Minas Gerais, Brazil.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:26 pm

ATLX

Atlas Lithium Corporation (NASDAQ:ATLX) has received the operational permit for its Neves Project in Brazil, allowing it to proceed with lithium production. This milestone enables the company to assemble and operate its processing plant and develop open-pit mining operations.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:26 pm

LLY

Eli Lilly's mirikizumab shows promising long-term efficacy and safety in treating ulcerative colitis and Crohn's disease, with positive results from Phase 3 studies. The drug is approved for ulcerative colitis and under FDA review for Crohn's disease.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 4:05 pm

LCID

Lucid Group, Inc. (NASDAQ:LCID) announced that its Lucid Air models have received a five-star overall safety rating from the National Highway Traffic Safety Administration for 2025. This includes the Lucid Air Pure, Touring, Grand Touring, and Sapphire models.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:02 pm

OXY

Occidental Petroleum shares are trading lower due to geopolitical tensions in the Middle East. Israel's airstrikes on Iran did not target oil sites, which may have influenced the oil sector's stock performance.

Portfolio Pulse from Dylan Berman

October 28, 2024 | 3:33 pm

JNJ

Johnson & Johnson announced positive Phase 3 study results for Tremfya in treating Crohn's disease, showing significant clinical remission and endoscopic response. The drug is under FDA review for this use, following its approval for ulcerative colitis.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 3:32 pm